MedinCell

Global Expansion And Extended Patents Will Unlock Future Opportunities

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

05 Sep 25

AnalystConsensusTarget's Fair Value

€22.77

18.3% undervalued

05 Sep

€18.60

14.1%

9.9%

14.1%

9.9%

Edit anytime before Sep 5 8:16 PM. Then post Updates to your followers.

Author's Valuation

€22.8

18.3% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

€22.8

18.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

29.68%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.98%

Calculation

€70.47m

Earnings '28

18.66x

PE Ratio '28

€1.32b

Market Cap '28

€1.32b

Market Cap '28

48.52m

No. shares '28

€27.11

Share Price '28

€27.11 Share Price '28

Discounted to 2025 @ 5.98% p.a.

€22.77

Fair Value '25